Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Estrogen Plays Surprise Role in Breast Cancer Treatment

Study finds it may slow disease if anti-estrogen therapies stop working

By Amanda Gardner
HealthDay Reporter


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
AIDS and HIV Infection
Amenorrhea
Amniocentesis
More...

Related Healthscout Videos
 border=
Optimistic Healing
Early Babies: How Soon is Too Soon?
Aqua Lipo
Cancer Treatment for Any Size
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Colon Cancer
Erectile Dysfunction
More...

Related Drug Information
 border=
Actonel
Cialis
Detrol LA
Diflucan
More...

Related News Articles
 border=
Diet Soda and Salt: Destroying your Kidneys?
Folate Levels in Pregnancy Tied to ADHD in Offspring
CDC Study Links 2 Antibiotics to Birth Defects
Switch to 'Light' Cigarettes Makes Quitting Tougher
More...

TUESDAY, Aug. 18 (HealthDay News) -- Researchers report that the paradoxical strategy of treating breast cancers that have become resistant to anti-estrogen therapies with estrogen actually shrank some tumors.

Not only that, but the estrogen made some of the tumors sensitive to anti-estrogen drugs once again.

Text Continues Below



The findings, reported in the Aug. 19 issue of the Journal of the American Medical Association, are preliminary, one expert cautioned.

"It's an interesting observation, but it needs to be expanded into a large trial," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "There's probably something biologically going on here that we don't quite understand. The question is, can we translate this into really clinically meaningful responses?"

"The history of treating patients with estrogen goes back to the 1940s when physicians started to treat patients with advanced breast cancer with diethylstilbestrol or DES [a synthetic estrogen]," explained Dr. Matthew Ellis, a professor of medicine at Washington University School of Medicine, an oncologist with the Siteman Cancer Center in St. Louis and a co-author of the study. "The ancient literature is full of grainy photographs with lung metastases or local, advanced breast cancer or bone metastases getting better with this paradoxical treatment."

That treatment protocol was displaced by the anti-estrogen therapy tamoxifen in the 1970s. And tamoxifen is now being replaced by stronger anti-estrogen drugs known as aromatase inhibitors.

"These drugs are a little more effective than tamoxifen ... so now you have a large population of patients with advanced breast cancer who have experienced treatment often with both estrogen-lowering agents," Ellis said. "We hypothesized that some of these patients could go back to estrogen therapy, but at a lower dose than anything looked at before."

Page:  1 | 2 | 3 | Next >>

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 8/18/2009

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





SOURCES: Matthew J. Ellis, M.B., BChir., Ph.D., professor, medicine, Washington University School of Medicine, and oncologist, Siteman Cancer Center, St. Louis; Ramona Swaby, M.D., assistant professor, medical oncology, Fox Chase Cancer Center, Philadelphia; Jay Brooks, chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Aug. 19, 2009, Journal of the American Medical Association


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy